The U.S. Food and Drug Administration has authorized Aletta from Vitestro, a robotic device designed to draw blood from a patient’s arm without requiring direct manual intervention by an operator throughout the procedure. The agency considers the device the first of its kind and believes its technology could help address the shortage of phlebotomists in the United States.
Aletta combines imaging, robotics, and artificial intelligence to identify veins, guide needle insertion, and collect blood samples. The system uses multiple forms of ultrasound imaging to locate veins and distinguish them from arteries, then handles the stages of the procedure from applying the tourniquet to covering the needle-puncture site with a bandage.
The Specialist’s Role After Automation
The device does not eliminate the need for a trained specialist, but it changes the nature of that person’s role during the draw. According to details provided by the Food and Drug Administration, the phlebotomist’s supervision is limited to ensuring that the collection tubes are filled in the correct order, verifying that they contain a sufficient volume after the procedure is complete, and responding to alerts issued by the device.
A specialist is still required to clean Aletta between patients. The Food and Drug Administration expects one specialist to be able to supervise up to three devices, which could increase operational capacity at sites that perform large numbers of sample collections, without eliminating the need for qualified personnel entirely.
Why Does This Authorization Matter?
The decision’s impact is not limited to making Vitestro’s device available in the United States. Aletta was authorized through the De Novo pathway, and the agency accompanied the authorization with special controls establishing performance requirements, clinical testing, and labeling conditions for similar robotic devices. These controls allow companies developing subsequent devices to use the 510(k) pathway to reach the market if they meet the specified requirements.
In practical terms, the decision establishes an initial regulatory framework for a category of robotic blood-draw devices, rather than evaluating every future device in a complete regulatory vacuum. However, it does not constitute general approval for all similar systems; other devices will still be required to demonstrate compliance with the performance, safety, and testing requirements established by the agency.
Funding and Commercial Expansion
Vitestro raised $70 million in March to support the device’s introduction to the U.S. market. The round included the venture capital arm of Labcorp, which employs phlebotomists to collect samples and send them to its laboratories, as well as Mayo Clinic, Sutter Health, and Fred Moll, co-founder of Intuitive.
Aletta received the CE mark in 2024, allowing the company to begin a limited rollout in Europe. Following the Series B funding round, Vitestro planned to expand commercial adoption in stages, starting in Europe and then moving toward the United States, with the funding allocated to expanding manufacturing, clinical expansion, and developing its commercial infrastructure.
The company is also working on a next-generation device intended to integrate more deeply into high-volume clinical workflows.